0753 GMT - UltraGreen.ai's 2026 revenue is likely to miss its guidance as competitive pressure emerged in 4Q, earlier than the diagnostic imaging dye maker previously expected, say DBS Group Research's Amanda Tan in a note. UltraGreen's volume losses to competitor Zydus Lifesciences are likely to exceed the bank's prior expectations, as Zydus started marketing its product in August, before UltraGreen relaunched its generic version, she says. This likely allowed Zydus to secure price-sensitive accounts before UltraGreen could respond, she says. The analyst trims her 2026-2027 earnings estimates by 4%-13% to reflect likely volume pressure and weaker pricing. DBS cuts its target price to 50 cents from 65 cents and maintains a hold rating. Shares fall 4.2% to US$0.455.
Comments